Cell Replacement Strategies Aimed at Reconstitution of the β-Cell Compartment in Type 1 Diabetes
- Giuseppe Orlando1⇑,
- Pierre Gianello2,
- Marcus Salvatori3,
- Robert J. Stratta1,
- Shay Soker1,
- Camillo Ricordi4 and
- Juan Domínguez-Bendala4
- 1Wake Forest School of Medicine, Winston-Salem, NC
- 2Université Catholique de Louvain, Brussels, Belgium
- 3Oxford University Hospitals NHS Trust, Oxford, U.K.
- 4Diabetes Research Institute, University of Miami, Miami, FL
- Corresponding author: Giuseppe Orlando, .
Emerging technologies in regenerative medicine have the potential to restore the β-cell compartment in diabetic patients, thereby overcoming the inadequacies of current treatment strategies and organ supply. Novel approaches include: 1) Encapsulation technology that protects islet transplants from host immune surveillance; 2) stem cell therapies and cellular reprogramming, which seek to regenerate the depleted β-cell compartment; and 3) whole-organ bioengineering, which capitalizes on the innate properties of the pancreas extracellular matrix to drive cellular repopulation. Collaborative efforts across these subfields of regenerative medicine seek to ultimately produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes.
- Received November 13, 2013.
- Accepted January 9, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.